Unit of Dermatology and Skin Research Laboratory, Galilee Medical Center, Nahariya, Israel.
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Arch Dermatol Res. 2023 Dec;315(10):2845-2851. doi: 10.1007/s00403-023-02693-4. Epub 2023 Aug 29.
The association of hidradenitis suppurativa (HS) and asthma remains to be investigated. To assess the bidirectional association between HS and asthma. A population-based study was conducted to compare HS patients (n = 6779) with age-, sex-, and ethnicity-matched control subjects (n = 33,259) with regard to the incidence of new onset and the prevalence of preexisting asthma. Adjusted hazard ratios (HRs) and adjusted odds ratios (ORs) were calculated. The prevalence of preexisting asthma was higher in patients with HS relative to controls (9.6% vs. 6.9%, respectively; P < 0.001). The odds of HS were 1.4-fold greater in patients with a history of asthma (fully adjusted OR 1.41; 95% CI 1.27-1.55; P < 0.001). The incidence rate of new-onset asthma was estimated at 9.0 (95% CI 6.3-12.7) and 6.2 (95% CI 5.1-7.5) cases per 10,000 person-years among patients with HS and controls, respectively. The risk of asthma was not statistically different in patients with HS and controls (fully adjusted HR 1.53; 95% CI 0.98-2.38; P = 0.062). Relative to other patients with HS, those with HS and comorbid asthma were younger at the onset of HS (30.7 [14.7] vs. 33.3 [15.1], respectively; P < 0.001) and had a comparable risk of all-cause mortality (adjusted HR 0.86; 95% CI 0.44-1.68; P = 0.660). A history of asthma confers susceptibility to subsequent development of HS. This observation is of importance for clinicians managing both patients with HS and asthma. Further research is warranted to elucidate the pathomechanism underlying this finding.
化脓性汗腺炎(HS)与哮喘之间的关联仍有待研究。为了评估 HS 与哮喘之间的双向关联,进行了一项基于人群的研究,比较了 6779 例 HS 患者(n = 6779)和年龄、性别和种族匹配的对照患者(n = 33259)新发哮喘的发生率和既往哮喘的患病率。计算了调整后的风险比(HR)和调整后的优势比(OR)。与对照组相比,HS 患者的既往哮喘患病率更高(分别为 9.6%和 6.9%;P < 0.001)。有哮喘病史的 HS 患者发生 HS 的几率高 1.4 倍(完全调整后的 OR 1.41;95%CI 1.27-1.55;P < 0.001)。HS 患者和对照组新发哮喘的发生率估计分别为每 10000 人年 9.0(95%CI 6.3-12.7)和 6.2(95%CI 5.1-7.5)例。在 HS 患者和对照组中,哮喘的风险无统计学差异(完全调整后的 HR 1.53;95%CI 0.98-2.38;P = 0.062)。与其他 HS 患者相比,伴有哮喘的 HS 患者 HS 发病年龄更小(分别为 30.7 [14.7]和 33.3 [15.1];P < 0.001),全因死亡率的风险相当(调整后的 HR 0.86;95%CI 0.44-1.68;P = 0.660)。哮喘病史使患者易发生随后的 HS 发展。这一观察结果对管理 HS 和哮喘的临床医生具有重要意义。需要进一步的研究来阐明这一发现的病理机制。
J Am Acad Dermatol. 2021-12
Br J Dermatol. 2024-8-14
Int J Dermatol. 2024-11
J Am Acad Dermatol. 2023-5
Interact J Med Res. 2025-2-18
Allergy Asthma Clin Immunol. 2021-1-6
J Am Acad Dermatol. 2021-12
JCI Insight. 2020-10-2
J Am Acad Dermatol. 2021-7
J Eur Acad Dermatol Venereol. 2021-1
JAMA Dermatol. 2020-7-1
J Am Acad Dermatol. 2019-10-9